Skip to main content

Pietenpol Lab

Pietenpol Lab Publications

2017

Jovanović B , Mayer IA , Mayer EL , Abramson VG , Bardia A , Sanders ME , Kuba MG , Estrada MV , Beeler JS , Shaver TM , Johnson KC , Sanchez V , Rosenbluth JM , Dillon PM , Forero-Torres A , Chang JC , Meszoely IM , Grau AM , Lehmann BD , Shyr Y , Sheng Q , Chen SC , Arteaga CL , Pietenpol JA , A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67 Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Mar 07; 23 (15). 4035-4045
Jovanović B , Sheng Q , Seitz RS , Lawrence KD , Morris SW , Thomas LR , Hout DR , Schweitzer BL , Guo Y , Pietenpol JA , Lehmann BD , Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue BMC cancer. 2017 Apr 04; 17 (1). 241

2016

Marshall CB , Mays DJ , Beeler JS , Rosenbluth JM , Boyd KL , Santos Guasch GL , Shaver TM , Tang LJ , Liu Q , Shyr Y , Venters BJ , Magnuson MA , Pietenpol JA , p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network Cell reports. 2016 Mar 03; 14 (10). 2289-300
Shaver TM , Lehmann BD , Beeler JS , Li CI , Li Z , Jin H , Stricker TP , Shyr Y , Pietenpol JA , Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies Cancer research. 2016 May 26; 76 (16). 4850-60
Lehmann BD , Jovanović B , Chen X , Estrada MV , Johnson KN , Shyr Y , Moses HL , Sanders ME , Pietenpol JA , Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection PloS one. 2016 Jun 16; 11 (6). e0157368